We are trying to target the bcr-abl protein in plasma and extracellular vescicles (derived from patients affected by chronic myeloid leukemia) using western blot. Despite the predicted molecular weight (210 kDa)
we obtain almost 3 bands with different molecular weights (more than 250, 250 and 100 kDa). We are trying to identify the band size which correlates to bcr/abl.
Hi Claudia
I am rather intrigued. What's the purpose of developing antibody against bcr-abl chimeric protein? Is it for therapeutics? This protein is intracellular and its action is intra-nuclear. How will a therapeutic antibody against this protein get to the target and neutralise it? TKI are very smart molecules capable of inhibiting transcription. How will anti bcr-abl antibody will work? I would be very interested to know. Best wishes. Siva
- Badges
- Science method
- Similar topics
- Teaching